| 1. |
Sorsby A, Mason MEA fundus dystrophy with unusual features[J]. Br J Ophthalmol19493326797. DOI:10.1136/bjo.33.2.67.
|
| 2. |
Capon MR, Polkinghorne PJ, Fitzke FW, et al. Sorsby's pseudoinflammatory macula dystrophy--Sorsby's fundus dystrophies[J]. Eye (Lond), 1988, 2 ( Pt 1): 114-122. DOI:10.1038/eye.1988.23.
|
| 3. |
Anand-Apte B, Chao JR, Singh R, et alSorsby fundus dystrophy: insights from the past and looking to the future[J]. J Neurosci Res20199718897. DOI:10.1002/jnr.24317.
|
| 4. |
Gourier HC, Chong NVCan Novel treatment of age-related macular degeneration be developed by better understanding of Sorsby's fundus dystrophy[J]. J Clin Med201545874883. DOI:10.3390/jcm4050874.
|
| 5. |
Weber BH, Vogt G, Pruett RC, et alMutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy[J]. Nat Genet199484352356. DOI:10.1038/ng1294-352.
|
| 6. |
Tsokolas G. Sorsby fundus dystrophy (SFD): a narrative review[J/OL]. Medicine (Baltimore), 2022, 101(38): e30595[2022-09-23]. https://europepmc.org/article/MED/36197222.
|
| 7. |
Biasella F, Plössl K, Baird PN, et al. The extracellular microenvironment in immune dysregulation and inflammation in retinal disorders[J/OL]. Front Immunol, 2023, 14: 1147037[2023-03-01]. https://europepmc.org/article/MED/36936905.
|
| 8. |
Weber BH, Lin B, White K, et alA mouse model for Sorsby fundus dystrophy[J]. Invest Ophthalmol Vis Sci200243827322740.
|
| 9. |
Spaide RFTreatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication[J]. Eye (Lond)202236918101812. DOI:10.1038/s41433-021-01735-3.
|
| 10. |
Baston A, Gerhardt C, Zandi S, et alVisual outcome after intravitreal anti-VEGF therapy for macular neovascularisation secondary to Sorsby's fundus dystrophy: a systematic review[J]. J Clin Med202110112433. DOI:10.3390/jcm10112433.
|
